WNT3A and colorectal carcinoma: We first evaluated p38α and β-catenin protein localization after activation of the Wnt pathway (mediated by serum supplementation or addition of Wnt3a and TWS-119), followed by inhibition of p38α with ralimetinib, in HT-29 CRC cell lines.